PCM
KPTI icon

Prelude Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Prelude Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-28,723
Closed -$211K – 1421
2025
Q4 		$211K Buy
+28,723
New +$176K 0.02% 1027
2024
Q2 		– Sell
-1,567
Closed -$35.5K – 1368
2024
Q1 		$35.5K Buy
+1,567
New +$27.5K ﹤0.01% 1265
2023
Q3 		– Sell
-1,062
Closed -$28.5K – 1251
2023
Q2 		$28.5K Sell
1,062
-1,766
-62% -$76.1K ﹤0.01% 1001
2023
Q1 		$165K Sell
2,828
-1,074
-28% -$53K 0.01% 897
2022
Q4 		$199K Buy
3,902
+3,003
+334% +$208K 0.01% 972
2022
Q3 		$74K Buy
899
+113
+14% +$8.44K ﹤0.01% 1201
2022
Q2 		$53K Buy
+786
New +$72.1K ﹤0.01% 1475
2022
Q1 		– Sell
-1,400
Closed -$135K – 2038
2021
Q4 		$135K Hold
1,400
– – ﹤0.01% 1657
2021
Q3 		$122K Hold
1,400
– – ﹤0.01% 1472
2021
Q2 		$217K Hold
1,400
– – 0.01% 1350
2021
Q1 		$221K Buy
1,400
+173
+14% +$36.5K 0.01% 1286
2020
Q4 		$285K Hold
1,227
– – 0.01% 934
2020
Q3 		$269K Sell
1,227
-41
-3% -$10K 0.01% 598
2020
Q2 		$360K Buy
+1,268
New +$375K 0.02% 568
2020
Q1 		– Sell
-9
Closed -$3K – 1750
2019
Q4 		$3K Buy
+9
New +$1.95K ﹤0.01% 1810
2019
Q3 		– Sell
-102
Closed -$9K – 1890
2019
Q2 		$9K Buy
102
+81
+386% +$6.5K ﹤0.01% 1424
2019
Q1 		$2K Sell
21
-3
-13% -$333 ﹤0.01% 1680
2018
Q4 		$3K Sell
24
-9
-27% -$1.52K ﹤0.01% 1669
2018
Q3 		$8K Buy
33
+14
+74% +$3.87K ﹤0.01% 1530
2018
Q2 		$5K Buy
+19
New +$4.7K ﹤0.01% 1558
2017
Q4 		– Sell
-120
Closed -$20K – 1544
2017
Q3 		$20K Buy
+120
New +$17.2K ﹤0.01% 1319
2017
Q1 		– Sell
-2,146
Closed -$303K – 1632
2016
Q4 		$303K Buy
+2,146
New +$290K 0.04% 437

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Prelude Capital Management's KPTI Position: Q1 2026 in Review

Prelude Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2026, closing a stake of 28,723 shares — an estimated $211K sold.

Prelude Capital Management first reported a position in KPTI in Q4 2016 and held it in 22 quarters. The position peaked at $360K in Q2 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Prelude Capital Management reported no remaining Karyopharm Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 28,723 Karyopharm Therapeutics shares in Q1 2026, an estimated $211K.
  • Prelude Capital Management first reported a position in Karyopharm Therapeutics in Q4 2016 and held it in 22 quarters.
  • Prelude Capital Management's Karyopharm Therapeutics position peaked at $360K in Q2 2020.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.